The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

The aim of the present study is to investigate the effects of canagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, on non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) in a mouse model of diabetes and NASH-HCC. First, mice aged five weeks w...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Int J Mol Sci
Main Authors: Jojima, Teruo, Wakamatsu, Sho, Kase, Masato, Iijima, Toshie, Maejima, Yuko, Shimomura, Kenju, Kogai, Takahiko, Tomaru, Takuya, Usui, Isao, Aso, Yoshimasa
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2019
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6829338/
https://ncbi.nlm.nih.gov/pubmed/31652578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20205237
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים